Journal article
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer
DS Binns, A Pirzkall, W Yu, J Callahan, L Mileshkin, P Conti, AM Scott, D MacFarlane, BM Fine, RJ Hicks
European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2011
Abstract
Purpose: The Response Evaluation Criteria in Solid Tumors (RECIST) are widely used but have recognized limitations. Molecular imaging assessments, including changes in 18F-deoxyglucose (FDG) or 18F- deoxythymidine (FLT) uptake by positron emission tomography (PET), may provide earlier, more robust evaluation of treatment efficacy. Methods: A prospective trial evaluated on-treatment changes in FDG and FLT PET imaging among patients with relapsed or recurrent non-small cell lung cancer treated with erlotinib to assess the relationship between PET-evaluated response and clinical outcomes. We describe an audit of compliance with the study imaging charter, to establish the feasibility of achievin..
View full abstractGrants
Funding Acknowledgements
This work was supported financially by Genentech, Inc., South San Francisco, CA, USA. Drs. Pirzkall, Yu and Fine are employees at Genentech, Inc., and own stock with F. Hoffmann-La Roche, Ltd.